中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.022 seconds)

    Whole Blood Assay for Measuring AMPK Activation
    6.
    发明申请
    Whole Blood Assay for Measuring AMPK Activation 有权
    全血测定AMPK激活

    公开(公告)号：US20150168408A1

    公开(公告)日：2015-06-18

    申请号：US14636041

    申请日：2015-03-02

    Applicant: Rigel Pharmaceuticals, Inc.

    Inventor： Vadim Markovtsov ,  Yasumichi Hitoshi

    IPC: G01N33/573

    CPC classification number: G01N33/573 ,  G01N33/49 ,  G01N33/4915 ,  G01N33/5041 ,  G01N33/53 ,  G01N2333/912 ,  G01N2333/91205 ,  G01N2800/02

    Abstract: A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.

    Abstract translation: 提供了样品分析的方法。 在某些实施方案中，所述方法包括：a）使用特异性结合磷酸化AMPK或其磷酸化靶标的抗体标记血液样品的细胞，以产生标记的样品; 和b）使用流式细胞术测量标记样品的血细胞群体的抗体结合。 在具体实施方案中，该方法还可以包括在标记步骤之前：离体或体内使血液与测试试剂接触; 并将评估与从血细胞的参考样品获得的结果进行比较。

    Method for treatment of COVID-19-associated conditions
    7.
    发明授权
    Method for treatment of COVID-19-associated conditions 有权

    公开(公告)号：US12263180B2

    公开(公告)日：2025-04-01

    申请号：US17323901

    申请日：2021-05-18

    Applicant: Rigel Pharmaceuticals, Inc.

    Inventor： Esteban Masuda ,  Vadim Markovtsov

    IPC: A61K31/5383 ,  A61K31/155 ,  A61K31/245 ,  A61K31/427 ,  A61K31/4706 ,  A61K31/4748 ,  A61K31/519 ,  A61K31/573 ,  A61K31/675 ,  A61K31/7048 ,  A61K39/42 ,  A61P31/14 ,  C07K16/10

    Abstract: Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.

    METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS
    8.
    发明申请
    METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS 有权

    公开(公告)号：US20210283152A1

    公开(公告)日：2021-09-16

    申请号：US17323901

    申请日：2021-05-18

    Applicant: Rigel Pharmaceuticals, Inc.

    Inventor： Esteban Masuda ,  Vadim Markovtsov

    IPC: A61K31/675 ,  A61K31/245 ,  A61K31/155 ,  A61K31/4706 ,  A61K31/427 ,  A61K31/573 ,  A61K31/519 ,  A61K39/42 ,  A61K31/4748 ,  A61K31/7048 ,  A61P31/14

    Abstract: Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.

Patent Agency Ranking